Ibrutinib therapy results in atrial fibrillation through modulation of the Src-Erk1/2 pathway

Le résumé fourni par la source

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has revolutionized treatment for B-cell malignancies but increases the incidence of atrial fibrillation (AF) compared to conventional chemotherapy. The downstream signaling pathways through which ibrutinib leads to AF are unknown and may represent a novel molecular mechanism for AF. To identify kinase signaling pathways that promote atrial fibrillation during ibrutinib therapy. Studies were performed in human atrial-specific cardiomyocytes derived from population control induced pluripotent stem cells (hiPSC-aCMs). Electrophysiologic measurements, including extracellular field potentials (EFPs), were conducted with the Nanion CardioExcyte96 system. Human phospho-kinase arrays determined the relative phosphorylation of 37 kinases in hiPSC-aCMs treated with either ibrutinib or vehicle control. Extracellular field potentials demonstrated a marked increase in spontaneous beat-to-beat variability, an in vitro correlate of arrhythmogenic behavior, with exposure to ibrutinib but not to second or third-generation BTK inhibitors, which are less associated with AF. Treatment with ibrutinib increased phosphorylation of multiple kinases (Src, Erk1/2, CREB) in the Src-Erk1/2 pathway; the most significant increase was with Erk1/2 phosphorylation (threefold). Pre-treatment of hiPSC-aCMs with the Erk1/2 inhibitors ulixertinib and SCH772984 inhibited the EFP arrhythmogenic signal seen with ibrutinib. In hiPSC-aCMs, ibrutinib treatment leads to increased arrhythmogenic behavior via the Src-Erk1/2 phosphorylation pathway. The inhibition of Erk1/2 or its downstream targets may represent novel pathways in the development of atrial fibrillation, providing new targets for therapeutic development.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.